Sonidegib

證據等級: L5

預測適應症: 10 個

Sonidegib: From Basal Cell Carcinoma to Medulloblastoma with Extensive Nodularity

One-Sentence Summary

Sonidegib is a Smoothened (SMO) antagonist referenced in this evidence pack in the context of basal cell carcinoma (BCC) treatment (its structured “original indication” field is itself a data gap). The TxGNN model predicts a 99.90% score for medulloblastoma with extensive nodularity, a Hedgehog-pathway-driven pediatric brain tumour subtype — but this evidence pack contains zero registered clinical trials and zero indexed publications for that specific drug–disease pair.

Quick Overview

Item	Content
Original Indication	Not available in structured drug record (data gap); referenced only indirectly as basal cell carcinoma (BCC) within the repurposing rationale text
Predicted New Indication	Medulloblastoma with extensive nodularity
TxGNN Prediction Score	99.90%
Evidence Level	L5 (see caveat below)
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Caveat on Evidence Level / Decision: the pack’s internal scoring field labels this candidate L2 / S2 / “Proceed with Guardrails,” but its own evidence.clinical_trials and evidence.literature arrays for this indication are empty, and the rationale text explicitly states the count fields are 0. Applying the evidence-level rule literally (based on actual trial/literature counts, not the internal label) gives L5 — model prediction only, no actual studies. Combined with a Blocking-severity data gap (missing TFDA/SmPC label data, meaning safety pre-assessment cannot even begin), this report recommends Hold rather than the pack’s internal “Proceed with Guardrails.”

Why is This Prediction Reasonable?

Sonidegib is a Smoothened (SMO) antagonist that selectively inhibits the Hedgehog signalling pathway. This mechanism-of-action detail comes from the repurposing rationale field, since the drug’s own original_moa field is a data gap.

SHH-activated medulloblastoma — including the “extensive nodularity” subtype — is a pediatric brain tumour known to be driven by aberrant activation of the Hedgehog pathway. Mechanistically, this is one of the most direct links in the entire candidate list: SMO inhibition should, in principle, act on the same driver pathway underlying this tumour subtype, in the same way it does in Hedgehog-pathway-driven BCC.

For context, the pack also lists four other predicted indications (xeroderma pigmentosum, annular epidermolytic ichthyosis, epidermolysis bullosa simplex with mottled pigmentation, trichothiodystrophy photosensitive) at similarly high TxGNN scores. The pack’s own rationale flags these as likely artefacts of knowledge-graph clustering around “rare photosensitive/genetic skin disease” — none has a plausible Hedgehog-pathway mechanism, and all are marked Hold. This makes medulloblastoma the only mechanistically credible candidate among the ten entries, even though it currently lacks any supporting trial or literature record in this pack.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Denmark Market Information

Sonidegib holds no marketing authorisation in Denmark (0 licenses on file; market status: not marketed). No national (Lægemiddelstyrelsen) or centralised (EMA) authorisation records are present in this evidence pack.

Cytotoxicity

Sonidegib is an antineoplastic agent (Hedgehog-pathway inhibitor used in oncology), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (SMO/Hedgehog-pathway inhibitor) — not a conventional cytotoxic agent
Myelosuppression Risk	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Emetogenicity Classification	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Monitoring Items	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Handling Protection	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. No key warnings, contraindications, or drug–drug interaction data are available in this evidence pack — the DDI query returned no results, and the TFDA/SmPC label data item is flagged as a Blocking data gap (DG001), meaning a Stage-1 safety pre-assessment cannot currently be performed.

Conclusion and Next Steps

Decision: Hold

Rationale:

A Blocking-severity data gap (missing TFDA/SmPC label data) prevents any Stage-1 safety pre-assessment, regardless of the strength of the mechanistic rationale.
Despite a mechanistically credible link (SMO inhibition → SHH-driven medulloblastoma), this evidence pack contains zero clinical trials and zero publications for this specific drug–disease pair — actual evidence level is L5, not the pack’s internal L2 label.
Sonidegib has no marketing authorisation in Denmark, so there is no existing regulatory or supply pathway to build on.

To proceed, the following is needed:

TFDA/SmPC label data (warnings, contraindications) to close the Blocking data gap
Confirmed original indication and MOA data for the drug record (currently both data gaps)
A targeted literature/trial search specifically for sonidegib in SHH-activated medulloblastoma (e.g., pediatric brain tumour consortium studies), since none surfaced in the automated queries logged here
Assessment of route/dosage-form compatibility for the pediatric population typically affected by this tumour subtype (currently marked “pending” with no data)
Full DDI profile (current query returned no results)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.